CBE1 Activators
Forskolin is known for its ability to elevate intracellular cAMP levels, which in turn can activate protein kinase A (PKA). The activation of PKA may lead to phosphorylation events that could potentially result in the activation of CBE1, assuming it is a substrate or is regulated by PKA-mediated pathways. Similarly, IBMX functions as a non-selective inhibitor of phosphodiesterases, which normally degrade cAMP. By preventing cAMP breakdown, IBMX prolongs the action of PKA and could thereby contribute to sustained CBE1 activation through prolonged phosphorylation. PMA, on the other hand, is a potent activator of protein kinase C (PKC), which is implicated in a myriad of signaling cascades. The activation of PKC might influence the phosphorylation state and activity of numerous proteins, including CBE1, either directly or via a complex signaling network.
Ionomycin serves as a calcium ionophore, raising intracellular calcium levels and potentially activating calcium-dependent proteins such as calmodulin-dependent kinases (CaMKs). These kinases might then modulate the activity of CBE1 through calcium-dependent signaling events. Genistein, by inhibiting certain tyrosine kinases, could alter the phosphorylation states of proteins within the cellular signaling apparatus, potentially creating a cascade effect that leads to the activation of CBE1. LY294002 and PD98059 are inhibitors of PI3K and MEK, respectively. While inhibition might seem counterintuitive as a means of activation, the complex feedback loops and cross-talk within cells often result in compensatory effects that can activate alternative pathways or proteins, potentially including CBE1. Finally, Trichostatin A and 5-Azacytidine act at the epigenetic level, influencing gene expression by inhibiting histone deacetylases and DNA methyltransferases, respectively. These changes in chromatin structure and gene expression patterns can have far-reaching impacts on protein levels and activities, including the potential upregulation and activation of CBE1.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) inhibits phosphodiesterases, preventing cAMP breakdown, which sustains PKA activity. The sustained activity of PKA can lead to enhanced phosphorylation and activation of CBE1. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which can phosphorylate and activate proteins within the same pathway as CBE1, potentially leading to downstream activation of CBE1. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin increases intracellular calcium levels, which can activate calmodulin and calmodulin-dependent kinase (CaMK), potentially influencing the activity and state of CBE1. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that can modulate various signaling pathways. By inhibiting certain tyrosine kinases, it can alter the phosphorylation state of proteins and potentially activate CBE1. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which can lead to alterations in the AKT signaling pathway. Through this modulation, the activity of downstream targets, including CBE1, can be activated. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. By inhibiting upstream kinases, PD98059 can result in compensatory regulatory effects that may activate CBE1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can modulate inflammatory and stress response pathways. This modulation may lead to altered protein interactions and activation states, possibly including CBE1. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, similar to PD98059, that can influence the MAPK/ERK pathway and possibly lead to the activation of CBE1 by modifying the phosphorylation patterns of proteins within the pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. By altering chromatin structure and gene expression, it can affect the expression levels and function of proteins, potentially leading to the activation of CBE1. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, which can lead to demethylation and activation of certain genes. This change in gene expression can result in the upregulation and activation of CBE1. | ||||||